专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005089308A3 GENE EXPRESSION AND POLYMORPHISMS THAT INFLUENCE LUNG CANCER SUSCEPTIBILITY 审中-公开
标题翻译：影响肺癌可能性的基因表达和多态性
公开(公告)号：WO2005089308A3
公开(公告)日：2006-06-15
申请号：PCT/US2005008532
申请日：2005-03-14
申请人： UNIV OHIO STATE RES FOUND , YOU MING , WANG MIN
发明人： YOU MING , WANG MIN
IPC分类号： G01N33/566 , A61K35/00 , G01N33/543 , G01N33/574
CPC分类号： G01N33/57423
摘要： Methods are provided relating to the identification and treatment of cancers that involve altered expression of the polymerase (DNA directed) iota (POLI) (Pol ?) gene.
摘要翻译：提供涉及鉴定和治疗涉及改变聚合酶（DNA定向）ι（POLI）（Pol）基因表达的癌症的方法。

2. 发明申请

WO2007089774A2 COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS 审中-公开
标题翻译：用于治疗认知障碍的组合物和方法
公开(公告)号：WO2007089774A2
公开(公告)日：2007-08-09
申请号：PCT/US2007002527
申请日：2007-01-31
申请人： UNIV YALE , ARNSTEN AMY F T , WANG MIN , MCCORMICK DAVID A , RAMOS BRIAN P
发明人： ARNSTEN AMY F T , WANG MIN , MCCORMICK DAVID A , RAMOS BRIAN P
IPC分类号： A61K31/505
CPC分类号： A61K31/505 , A61K31/155 , A61K45/06 , C07D239/48 , A61K2300/00
摘要： The present invention relates to the use of inhibitors or blockers of I h (hyperpolarization-activated cationic current) channels in the treatment of cognitive disorders. In preferred aspects of the present invention, an effective amount of a compound is administered to a patient in need, wherein the compound has the chemical structure: Where R 1 is H, or an optionally substituted C 1 -C 3 alkyl, preferably a C 2 alkyl (ethyl) group; R 2 is an optionally substituted C 1 -C 3 alkyl group, preferably a methyl group; R 3 is H, an optionally substitutedC 1 -C 3 alkyl (preferably methyl), a halogen or 0(Ci-Ca) alkyl; R 4 is an optionally substituted C 1 -C 6 alkyl, C(O)-(C 1 -C 5 )alkyl, C(O)-aryl, C(O)O-(C 1 - C 4 )alkyl, C(O)O-aryl, or an optionally substituted heterocyclic, aryl or heteroaryl group; R 4 ais H or an optionally substituted C 1 -C 6 (preferably a C 1 -C 3 ) alkyl; R 5 , R 6 and R 7 are each independently H, halogen, an optionally substituted C 1 -C 6 alkyl (preferably, an optionally substituted C 1 -C 3 alkyl), 0-(C 1 -C 3 ) alkyl, or an optionally substituted heterocyclic, aryl or heteroaryl group; Y - is an anion of a pharmaceutically acceptable salt (a physiologically acceptable anion, preferably a Cl -, Br - , I - , OAc - ); or a solvate or polymorph thereof, optionally, in combination with guanfacine and/or chelerythrine, and a pharmaceutically acceptable carrier, additive or excipient to a patient in need of therapy.
摘要翻译：本发明涉及抑制剂或阻断剂（超极化活化的阳离子电流）通道在治疗认知障碍中的用途。在本发明的优选方面，向有需要的患者施用有效量的化合物，其中所述化合物具有以下化学结构：其中R 1为H，或任选取代的C _{3个）烷基; R 5，R 6和R 7各自独立地为H，卤素，任选取代的C 1 -C 烷基（优选任选取代的C 1 -C 3烷基），O-（C 1 -C 6 - 烷基） C 3烷基或任选取代的杂环，芳基或杂芳基; 是药学上可接受的盐（一种生理上可接受的阴离子，优选的是其中的一个）阴离子，，OAc - ）; 或其溶剂化物或多晶型物，任选地与胍法和/或螯合菊酯组合，以及药物可接受的载体，添加剂或赋形剂给需要治疗的患者。}

3. 发明申请

WO2009103183A8 UPLINK SCHEDULING IN WIRELESS NETWORKS 审中-公开
标题翻译：无线网络中的UPLINK调度
公开(公告)号：WO2009103183A8
公开(公告)日：2009-11-26
申请号：PCT/CN2008000363
申请日：2008-02-19
申请人： ERICSSON TELEFON AB L M , WANG MIN , FAN RUI
发明人： WANG MIN , FAN RUI
IPC分类号： H04L12/24
CPC分类号： H04W72/1221 , H04W72/1268 , H04W88/08
摘要： In network-based uplink scheduling, users are scheduled by the network for uplink communication between a user side and a network side. In this context, the invention provides an efficient estimation of User Equipment (UE) buffer status on the network side such as at Node B (20), for each of a number of users (10), and determines an uplink scheduling priority order of the users based on the network-estimated buffer status information. The users (10) are allocated communication resources based on the determined uplink scheduling priority order. In this way, the UE buffer status may be considered in the uplink scheduling procedure without explicit UE buffer status reports (that would waste valuable uplink transmission resources) from the UE side. This means that efficient scheduling and optimal exploitation of the uplink transmission resources are ensured, with clearly improved system performance as a result.
摘要翻译：在基于网络的上行链路调度中，用户由网络进行调度，用于用户侧和网络侧之间的上行链路通信。在本文中，本发明为多个用户（10）中的每个用户（10）提供对诸如在节点B（20）的网络侧的用户设备（UE）缓冲器状态的有效估计，并且确定上行链路调度优先级顺序用户基于网络估计的缓冲区状态信息。基于所确定的上行链路调度优先级顺序为用户（10）分配通信资源。以这种方式，可以在上行链路调度过程中考虑UE缓冲器状态，而没有来自UE侧的显式UE缓冲器状态报告（将浪费有价值的上行链路传输资源）。这意味着确保了上行链路传输资源的有效调度和优化利用，结果显着提高了系统性能。

4. 发明申请

WO2012139485A8 ORAL SOLID PREPARATION OF COMPOUND ANTITUBERCULOSIS DRUG AND PREPARATION METHOD THEREOF 审中-公开
标题翻译：复方抗凝血药物的口服固体制剂及其制备方法
公开(公告)号：WO2012139485A8
公开(公告)日：2013-10-10
申请号：PCT/CN2012073689
申请日：2012-04-10
申请人： ZHEJIANG HISUN PHARM CO LTD , GU MAOJIAN , ZHENG QILAN , XU CHAO , LI NING , CHEN GUIXIAN , ZHENG LAN , WANG MIN , JIANG LINTAO
发明人： GU MAOJIAN , ZHENG QILAN , XU CHAO , LI NING , CHEN GUIXIAN , ZHENG LAN , WANG MIN , JIANG LINTAO
IPC分类号： A61K9/20 , A61K31/4409 , A61K31/496 , A61P31/06
CPC分类号： A61K9/286 , A61K9/2086 , A61K9/209 , A61K9/28 , A61K9/284 , A61K9/2866 , A61K9/2886 , A61K31/133 , A61K31/4409 , A61K31/496 , A61K31/4965 , A61K2300/00
摘要： An oral solid preparation of a compound antituberculosis drug, wherein the active ingredients are rifampicin, isoniazid, pyrazinamide and ethambutol hydrochloride. The compound oral solid preparation is a coated tablet with coated core or a coated three-layer tablet, wherein the two active ingredients rifampicin and isoniazid do not contact directly. The compound oral solid preparation not only improves the stability of the compound preparation, but also improves the bioavailability of rifampicin.
摘要翻译：一种复方抗结核药物的口服固体制剂，其中活性成分是利福平，异烟肼，吡嗪酰胺和盐酸乙胺丁醇。复合口服固体制剂是具有包衣核心或涂层三层片剂的包衣片剂，其中两种活性成分利福平和异烟肼不直接接触。复方口服固体制剂不仅提高了化合物制剂的稳定性，而且提高了利福平的生物利用度。

5. 发明申请

WO2011065874A1 METHOD AND ARRANGEMENTS FOR REDUCING THE NUMBER OF FAILED HANOVER PROCEDURES 审中-公开
标题翻译：减少失败程序数量的方法和安排
公开(公告)号：WO2011065874A1
公开(公告)日：2011-06-03
申请号：PCT/SE2009051333
申请日：2009-11-25
申请人： ERICSSON TELEFON AB L M , PETTERSSON JONAS , WERNERSSON MATS , WANG MIN , SANDLUND KRISTOFER , TIMNER YLVA
发明人： PETTERSSON JONAS , WERNERSSON MATS , WANG MIN , SANDLUND KRISTOFER , TIMNER YLVA
IPC分类号： H04W36/24 , H04W36/26
CPC分类号： H04W36/24 , H04W36/0055
摘要： The invention relates to a method in a source radio base station (14) for enabling a handover of a connection to a user equipment (13) from a source cell (11) to a target cell (17). The source radio base station (14) serves the source cell (11) and is comprised in a radio communications network (100). The source radio base station receives (802) at least a first segment of a measurement report from the user equipment (13), which measurement report indicates received signal power of signals of neighbouring cells. The source radio base station then determines (803) a transmission time of the segment of the measurement report and compares (804) the transmission time with a predefined time threshold value. When the transmission time has exceeded the time threshold value, the source radio base station determines (806) whether to perform the handover based on the at least first segment of the measurement report.
摘要翻译：本发明涉及一种源无线电基站（14）中的方法，用于实现从源小区（11）到目标小区（17）的到用户设备（13）的连接切换。源无线电基站（14）用于源小区（11）并且包括在无线电通信网络（100）中。源无线电基站从用户设备（13）接收（802）至少一个测量报告的第一段，该测量报告指示相邻小区的信号的接收信号功率。源无线电基站然后确定（803）测量报告的段的传输时间，并将传输时间与预定义的时间阈值进行比较（804）。当传输时间超过时间阈值时，源无线电基站基于测量报告的至少第一段确定（806）是否执行切换。

6. 发明申请

WO2007028147A3 IDENTIFICATION OF A PROSTATIC INTRAEPITHELIAL NEOPLASIA (PIN)-SPECIFIC GENE AND PROTEIN (PIN-1) USEFUL AS A DIAGNOSTIC TREATMENT FOR PROSTATE CANCER 审中-公开
标题翻译：鉴定前列腺特异性基因（PIN） - 特异性基因和蛋白（PIN-1）有助于前列腺癌的诊断治疗
公开(公告)号：WO2007028147A3
公开(公告)日：2009-04-23
申请号：PCT/US2006034470
申请日：2006-09-01
申请人： PHILADELPHIA HEALTH & EDUCATIO , STEARNS MARK E , HU YOUJI , WANG MIN
发明人： STEARNS MARK E , HU YOUJI , WANG MIN
IPC分类号： C12Q1/68 , A61K38/00 , C07K14/47
CPC分类号： G01N33/57434 , C12Q1/6886 , C12Q2600/136 , G01N2333/705
摘要： The invention relates to nucleic acids encoding a mammalian ABCA5 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, PIN. Further, the invention relates to diagnostic assays for identifying the DNA-binding protein ABCA5 (also known as PIN-I). The invention also relates to oligonucleotide sequence(s) or antibodies that specifically bind with ABCA5 or variants thereof.
摘要翻译：本发明涉及编码哺乳动物ABCA5基因的核酸和由此编码的蛋白质，其表达在某些疾病，病症或病症中增加，包括但不限于PIN。此外，本发明涉及用于鉴定DNA结合蛋白ABCA5（也称为PIN-I）的诊断测定。本发明还涉及与ABCA5或其变体特异性结合的寡核苷酸序列或抗体。

7. 发明申请

WO2007014319A2 MANAGING CONTENTION-FREE TIME ALLOCATIONS IN A NETWORK 审中-公开
标题翻译：管理网络中的免费时间分配
公开(公告)号：WO2007014319A2
公开(公告)日：2007-02-01
申请号：PCT/US2006029377
申请日：2006-07-27
申请人： INTELLON CORP , CONEXANT SYSTEMS INC , SHARP KK , RIEDEL NEAL K , KATAR SRINIVAS , YONGE III LAWRENCE W , WANG MIN , PEPONIDES GEORGE M , CHAN WAI CHUNG , GAVETTE SHERMAN LEON , AYYAGARI DEEPAK
发明人： KATAR SRINIVAS , YONGE III LAWRENCE W , WANG MIN , PEPONIDES GEORGE M , CHAN WAI CHUNG , GAVETTE SHERMAN LEON , AYYAGARI DEEPAK
IPC分类号： H04B7/212
CPC分类号： H04B7/2643 , H04B3/542 , H04B2203/5408
摘要： A method and corresponding system for communicating between stations (102A, 102B, 104A, 104B, 104C) in a network (100) are presented. The method includes providing repeated beacon transmissions (402) from a coordinator station for coordinating transmissions among a plurality of the stations; transmitting from a first station to a second station during a time slot assigned to the first station by at least one of the beacon transmissions; and transmitting from the first station information that grants permission to the second station to transmit during at least a portion (610) of a time slot assigned to the first station.
摘要翻译：提出了一种用于在网络（100）中的站（102A，102B，104A，104B，104C）之间进行通信的方法和对应系统。该方法包括从协调站提供重复的信标传输（402），用于协调多个站之间的传输; 在通过至少一个信标传输分配给第一站的时隙期间，从第一站向第二站发送; 以及从分配给所述第一站的时隙的至少一部分（610）期间向所述第一站发送授权给所述第二站的传输的信息。

8. 发明申请

WO2004001014A2 OSTEOPONTIN, OLIGODENDROCYTES AND MYELINATION 审中-公开
标题翻译：奥司他丁，奥利膦酸和血红蛋白
公开(公告)号：WO2004001014A2
公开(公告)日：2003-12-31
申请号：PCT/US0319864
申请日：2003-06-24
申请人： AVENTIS PHARMA INC , MERRILL JEAN , PU SU-FEN , KHORKOVA OLGA , JI ZHONGQI , CAMACHO FERNANDO , BUSCH STEVE , WANG MIN , CHEN TING , DINERSTEIN ROBERT J , YAO ZHENGBIN , CHEN YANGDE , ZHANG XIN , CHANDROSS KAREN , LEE LAN
发明人： MERRILL JEAN , PU SU-FEN , KHORKOVA OLGA , JI ZHONGQI , CAMACHO FERNANDO , BUSCH STEVE , WANG MIN , CHEN TING , DINERSTEIN ROBERT J , YAO ZHENGBIN , CHEN YANGDE , ZHANG XIN , CHANDROSS KAREN , LEE LAN
IPC分类号： C12Q1/02 , A61K38/00 , A61K39/395 , A61K45/00 , A61P25/00 , A61P25/28 , A61P43/00 , C12N5/079 , C12N
CPC分类号： G01N33/5058 , C07K16/24 , C12N5/0622 , C12N2501/585 , G01N33/5029 , G01N33/5073 , G01N2333/51 , G01N2800/285
摘要： Osteopontin is a marker for oligodendrocyte precursor cells. Osteopontin also modulates oligodendrocyte differentiation and central nervous system myelination. Osteopontin induces migration of oligodendrocyte precursors.
摘要翻译：骨桥蛋白是少突胶质细胞前体细胞的标记物。骨桥蛋白也调节少突胶质细胞分化和中枢神经系统髓鞘形成。骨桥蛋白诱导少突胶质细胞前体的迁移。

9. 发明申请

WO02083081A3 PROSTATE CANCER-RELATED COMPOSITIONS, METHODS AND KITS BASED ON DNA MACROARRAY PROTEMICS PLATFORMS 审中-公开
标题翻译：基于DNA宏观平台的前列腺癌相关组合物，方法和试剂盒
公开(公告)号：WO02083081A3
公开(公告)日：2002-12-12
申请号：PCT/US0208673
申请日：2002-03-21
申请人： PHILADELPHIA HEALTH & EDUCATIO , STEARNS MARK , HU YOUJI , WANG MIN
发明人： STEARNS MARK , HU YOUJI , WANG MIN
IPC分类号： A61K38/00 , C07K14/47 , C12Q1/68 , G01N33/574 , A61K35/14 , C07H5/04 , C07H5/06 , C07H19/00 , C07H21/00 , C07H21/04 , C07K1/00 , C07K2/00 , C07K4/00 , C07K5/00 , C07K7/00 , C07K14/00 , C07K16/00 , C07K17/00 , C08B37/00 , C12N15/00 , C12N15/09 , C12N15/63 , C12N15/70 , C12N15/74 , C12P21/06 , C12P21/08 , C12Q1/00 , G01N33/48 , G01N33/53 , G01N33/567
CPC分类号： G01N33/57434 , A61K38/00 , C07K14/4705 , C12Q1/6886 , C12Q2600/136 , Y10T436/25 , Y10T436/25125 , Y10T436/2525 , Y10T436/25375
摘要： The invention relates to novel nucleic acids encoding a mammalian PCAM-1 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, prostate cancer. The invention further relates to methods of detecting and treating prostate cancer, comprising modulating or detecting PCAM-1 expression and/or production and activity of PCAM-1 poly peptide. Further, the invention relates to novel assays for the identification of DNA-binding proteins and the double-stranded oligonucleotide sequences that specifically bind with them.
摘要翻译：本发明涉及编码哺乳动物PCAM-1基因的新型核酸及其编码的蛋白质，其表达在某些疾病，病症或病症（包括但不限于前列腺癌）中增加。本发明还涉及检测和治疗前列腺癌的方法，包括调节或检测PCAM-1多肽的PCAM-1表达和/或产生和活性。此外，本发明涉及用于鉴定DNA结合蛋白质的新型测定法和与其特异性结合的双链寡核苷酸序列。

10. 发明申请

WO03094844A2 PROSTATE CANCER-RELATED COMPOSITIONS, METHODS, AND KITS BASED ON DNA MACROARRAY PROTEOMICS PLATFORMS 审中-公开
标题翻译：基于DNA宏观调控平台的前列腺癌相关成分，方法和试剂盒
公开(公告)号：WO03094844A2
公开(公告)日：2003-11-20
申请号：PCT/US0314098
申请日：2003-05-07
申请人： PHILADELPHIA HEALTH & EDUCATIO , STEARNS MARK , HU YOUJI , WANG MIN
发明人： STEARNS MARK , HU YOUJI , WANG MIN
IPC分类号： B67D7/32 , A61K38/00 , B67D7/00 , C07K14/47 , C12P21/08 , C12Q1/68 , G01N33/574 , A61K
CPC分类号： C07K14/4705 , A61K38/00 , C07K14/4748 , C07K2319/20 , C07K2319/23 , C07K2319/40 , C12Q1/6886 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , G01N33/57434
摘要： The invention relates to novel nucleic acids encoding a mammalian PCADM-1 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, prostate cancer. The invention further relates to methods of detecting and treating prostate cancer, comprising modulating or detecting PCADM-1 expression and/or production and activity of PCADM-1 polypeptide. Further, the invention relates to novel assays for the identification of DNA-binding proteins and the double-stranded oligonucleotide sequences that specifically bind with them. Finally, the invention relates to DNAZYMs or DNA enzymes which specifically bind PCADM-1 mRNA to inhibit PCADM-1 gene expression and thereby destroy tumor cells and tumor tissue.
摘要翻译：本发明涉及编码哺乳动物PCADM-1基因的新型核酸和由此编码的蛋白质，其在某些疾病，病症或病症中的表达增加，包括但不限于前列腺癌。本发明还涉及检测和治疗前列腺癌的方法，包括调节或检测PCADM-1多肽的PCADM-1表达和/或产生和活性。此外，本发明涉及用于鉴定DNA结合蛋白质的新型测定法和与其特异性结合的双链寡核苷酸序列。最后，本发明涉及特异性结合PCADM-1mRNA以抑制PCADM-1基因表达从而破坏肿瘤细胞和肿瘤组织的DNAZYM或DNA酶。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式